Molecular Hybrids Integrated with Benzimidazole and Pyrazole Structural Motifs: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies

被引:51
作者
Sivaramakarthikeyan, Ramar [1 ]
Shunmugam, Iniyaval [1 ]
Vadivel, Saravanan [1 ]
Lim, Wei Meng [2 ]
Mai, Chun-Wai [2 ,3 ]
Ramalingan, Chennan [1 ]
机构
[1] Kalasalingam Acad Res & Educ Deemed Be Univ, Sch Adv Sci, Dept Chem, Krishnankoil 626126, Tamil Nadu, India
[2] Int Med Univ, Sch Pharm, Kuala Lumpur 57000, Malaysia
[3] Int Med Univ, Ctr Canc & Stem Cell Res, Inst Res Dev & Innovat IRDI, Kuala Lumpur 57000, Malaysia
来源
ACS OMEGA | 2020年 / 5卷 / 17期
关键词
2; CHK2; INHIBITORS; POTENTIAL ANTICANCER; CARBAZOLES SYNTHESIS; DERIVATIVES; DISCOVERY; SCAFFOLD; BENDAMUSTINE; MOIETY; DRUGS;
D O I
10.1021/acsomega.0c00630
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Synthesis of a series of benzimidazole-ornamented pyrazoles, 6a-6j has been obtained from arylhydrazine and aralkyl ketones via a multistep synthetic strategy. Among them, a hybridpossessing para-nitrophenyl moiety connected to a pyrazole scaffold (6a) exerted the highest anti-inflammatory activity, which is superior to the standard, diclofenac sodium. While executing the 2,2-diphenyl-1-picrylhydrazyl radical-scavenging activity, a hybrid-possessing para-bromophenyl unit integrated at the pyrazole structural motif (6i) exhibited the highest activity among the hybrids examined. Besides, evaluation of anticancer potency of the synthesized hybrids revealed that the one containing a para-fluorophenyl unit tethered at the pyrazole nucleus (6h) showed the highest activity against both the pancreatic cancer cells (SW1990 and AsPCl) investigated. Considerable binding affinity between B-cell lymphoma and the hybrid, 6h has been reflected while performing molecular docking studies (-8.65 kcal/mol). The outcomes of the investigation expose that these hybrids could be used as effective intermediates to construct more potent biological agents.
引用
收藏
页码:10089 / 10098
页数:10
相关论文
共 68 条
  • [1] Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents
    Abd El-Karim, Somaia S.
    Anwar, Manal M.
    Mohamed, Neama A.
    Nasr, Tamer
    Elseginy, Samia A.
    [J]. BIOORGANIC CHEMISTRY, 2015, 63 : 1 - 12
  • [2] Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors
    Akhtar, Md. Jawaid
    Khan, Ahsan Ahmed
    Ali, Zulphikar
    Dewangan, Rikeshwer Prasad
    Rafi, Md.
    Hassan, Md. Quamrul
    Akhtar, Md. Sayeed
    Siddiqui, Anees Ahmad
    Partap, Sangh
    Pasha, Santosh
    Yar, M. Shahar
    [J]. BIOORGANIC CHEMISTRY, 2018, 78 : 158 - 169
  • [3] Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents
    Alam, Raquib
    Wahi, Divya
    Singh, Raja
    Sinha, Devapriya
    Tandon, Vibha
    Grover, Abhinav
    Rahisuddin
    [J]. BIOORGANIC CHEMISTRY, 2016, 69 : 77 - 90
  • [4] Review: biologically active pyrazole derivatives
    Ansari, Anam
    Ali, Abad
    Asif, Mohd
    Shamsuzzaman
    [J]. NEW JOURNAL OF CHEMISTRY, 2017, 41 (01) : 16 - 41
  • [5] Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents
    Bayrak, Nilufer
    Yildirim, Hatice
    Yildiz, Mahmut
    Radwan, Mohamed O.
    Otsuka, Masami
    Fujita, Mikako
    Tuyun, Amac Fatih
    Ciftci, Halil, I
    [J]. BIOORGANIC CHEMISTRY, 2019, 92
  • [6] Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells
    Bozdag, Murat
    Ferraroni, Marta
    Ward, Carol
    Carta, Fabrizio
    Bua, Silvia
    Angeli, Andrea
    Langdon, Simon P.
    Kunkler, Ian H.
    Al-Tamimi, Abdul-Malek S.
    Supuran, Claudiu T.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182
  • [7] Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update
    Cheson, Bruce D.
    Brugger, Wolfram
    Damaj, Gandhi
    Dreyling, Martin
    Kahl, Brad
    Kimby, Eva
    Ogura, Michinori
    Weidmann, Eckhart
    Wendtner, Clemens-Martin
    Zinzani, Pier Luigi
    [J]. LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 766 - 782
  • [8] Bendamustine: Rebirth of an Old Drug
    Cheson, Bruce D.
    Rummel, Mathias J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1492 - 1501
  • [9] Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)
    Chung, Felicia Fei-Lei
    Tan, Perry Faith Tze Ming
    Raja, Vijay Joseph
    Tan, Boon-Shing
    Lim, Kuan-Hon
    Kam, Toh-Seok
    Hii, Ling-Wei
    Tan, Si Hoey
    See, Sze-Jia
    Tan, Yuen-Fen
    Wong, Li-Zhe
    Yam, Wai Keat
    Mai, Chun Wai
    Bradshaw, Tracey D.
    Leong, Chee-Onn
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [10] Privileged structures: Applications in drug discovery
    DeSimone, RW
    Currie, KS
    Mitchell, SA
    Darrow, JW
    Pippin, DA
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2004, 7 (05) : 473 - 493